Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | CASR | P41180 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15334134 | 0.87 | NPC1 (0.66) | NPC1SMN1; SMN2RAB9AKMT2AGAA | |
| SCHEMBL15339799 | 0.86 | MEN1 (0.56) | FAAHNPC1LMNASMN1; SMN2HPGD | |
| SCHEMBL2722883 | 0.85 | FAAH (0.53) | FAAHNPC1LMNASMN1; SMN2HPGD | |
| SCHEMBL4437536 | 0.85 | POLB (0.53) | FAAHNPC1LMNAHPGDRAB9A | |
| SCHEMBL2723278 | 0.85 | FAAH (0.57) | FAAHNPC1SMN1; SMN2HPGDRAB9A | |
| SCHEMBL2725301 | 0.83 | FAAH (0.60) | FAAHNPC1HPGDRAB9AMEN1 | |
| SCHEMBL2734060 | 0.82 | FAAH (0.53) | FAAHNPC1HPGDRAB9AMEN1 | |
| SCHEMBL3275628 | 0.80 | NPC1 (0.72) | NPC1LMNASMN1; SMN2HPGDRAB9A | |
| SCHEMBL31321645 | 0.79 | L3MBTL1 (0.56) | NPC1LMNASMN1; SMN2HPGDMEN1 | |
| SCHEMBL717950 | 0.79 | HPGD (0.63) | NPC1LMNAHPGDRAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249128-B2 | Anti-cancer serine hydrolase inhibitory carbamates | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249128-B2 | Anti-cancer serine hydrolase inhibitory carbamates | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-02-02 | — | — | US | disclosed |
| US-20130281453-A1 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281453-A1 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-10-24 | — | — | US | disclosed |
| WO-2012058115-A2 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | CRAVATT BENJAMIN (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281453-A1 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | AADAC, DDAH1, PRSS1 | FAAH 58/4885NPC1 2821/4885LMNA 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.